Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 3,100 shares, a decline of 27.9% from the October 15th total of 4,300 shares. Based on an average daily volume of 14,400 shares, the days-to-cover ratio is currently 0.2 days.
Adlai Nortye Stock Up 1.3 %
NASDAQ:ANL opened at $3.15 on Thursday. The stock has a 50-day simple moving average of $2.16 and a 200-day simple moving average of $4.53. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a research note on Monday.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
- Five stocks we like better than Adlai Nortye
- What to Know About Investing in Penny Stocks
- Rocket Lab is the Right Stock for the Right Time
- What is a Secondary Public Offering? What Investors Need to Know
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Bank Stocks – Best Bank Stocks to Invest In
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
